Dr. Mato on Sequencing and what is CLLAN - CLL Support

CLL Support

22,513 members38,668 posts

Dr. Mato on Sequencing and what is CLLAN

bkoffman profile image
bkoffmanCLL CURE Hero
6 Replies

Hi,

We have so many great drugs to treat CLL. How to sequence them is unclear, but Dr. Mato presents some reassuring data that when we use venetoclax, namely that we still have some good options when it stops working in this interview from ASH 2019 (cllsociety.org/2020/02/ash-....

CLLAN is an international “umbrella” charity organization helps CLL charities in Europe and the 3rd world that the CLL Society proudly supports. Learn more here (cllsociety.org/about-us/cll....

Stay strong.

We are all in this together.

Brian

Brian Koffman MDCM (retired) MS Ed

Co-Founder, Executive VP and Chief Medical Officer

CLL Society, Inc

cllsociety.org

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
6 Replies
maggiesgrandmom profile image
maggiesgrandmom

Thanks as always Dr. Koffman. I liked the interview with Dr. Mato and appreciated when you stopped him so as to clarify some of the terms he used so that others could comprehend his information more clearly.

johnl profile image
johnl

Brian, I'm currently on the I V trial at MDA. I reached 0.01% MRD at 15mos in the blood, same as I was at 12 mos. My bone marrow at 12 mos was 0.02%. Even if I reach UMRD4 at 18 mos I'm considering staying on Ibrutinib continuously after the trial. My reasons are that I also found out during this trial that I have 4-39 genes usage and a little ( less that 10%) notch 1 which put me at a higher risk for RT. So I think if the I V got me down this far on MRD, the Ibrutinib alone might be able to keep me there and at those low levels lessen my chance of Richters. I don't want to break treatment with Ibrutinib because it might increase the chance of resistance. So far no one has OKed this, but they haven't said no either.

Any comments on this strategy?

john

closh profile image
closh in reply to johnl

Hi John

Half of the MRD- participants on the Captivate (PCYC-1142) I+V trial stay on Ibrutinib. It's certainly an option under investigation.

Graham

johnl profile image
johnl in reply to closh

Thanks, I didn't know that.

john

bkoffman profile image
bkoffmanCLL CURE Hero in reply to johnl

Makes sense to me.

johnl profile image
johnl in reply to bkoffman

Thanks for your comment

john

You may also like...

Dr. Mato on what really happens when we must stop our ibrutinib or idelalisib

section of the CLL Society website, we’ve posted an interview from ASH 2015 with Dr. Anthony Mato...

ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance

to possibly avoid it:...

ASH 2016: Dr. Mato on real world data on ibrutinib

the interview or read the transcript here:...

Dr. O'Brien on how she treats CLL frontline and Dr. Pagel on new ways to block BTK

Co-Founder, Executive VP and Chief Medical Officer CLL Society, Inc. https://cllsociety.org

So much to share returning from Scotland for CLLAN Horizon and iwCLL

through our survey:...